The Challenge
A mid-cap pharmaceutical company aimed to in-license a late-stage asset in a novel therapeutic area. However, they lacked internal expertise, dedicated BI subscriptions, and an established KOL network in this new space.
The team needed to quickly validate the asset’s clinical superiority and commercial viability. They had to justify the licensing premium without losing the competitive bid.
The Omnitheia Solution
The client utilised Omnitheia’s Integrated Insights platform to execute end-to-end commercial due diligence, combining secondary landscape mapping with rapid primary market research.
- Competitive Mapping: Omnitheia’s AI instantly analysed live industry sources to map the unfamiliar therapeutic landscape, establishing a clear view of standard-of-care (SoC) treatments and competing pipeline assets.
- Data Integration: The client uploaded the target company’s data room files. Omnitheia cross-referenced the seller’s claims against published global data, validating clinical efficacy but flagging risks regarding projected market share.
- KOL Intelligence: To address market share flags, the platform instantly identified, vetted, and provided compliance-verified access to top-tier global KOLs and Payors matched to the asset’s mechanism of action (MoA).
- Expert Validation: Omnitheia’s in-house life science experts conducted custom interviews, safely probing complex clinical nuances and pricing thresholds to test the asset’s USPs against real-world prescribing habits.
Impact & Key Results
The BD team successfully executed comprehensive due diligence in a completely new therapeutic area without expanding their external vendor spend.
- Evidence-Backed Valuation: Our client was able to build a robust, defensible rNPV (risk-adjusted net present valuation) using a well-rounded methodology that combined real-world evidence and curated market data sources.
- Accelerated Deal Validation: Delivered a fully triangulated, data-backed licensing valuation in days instead of months.
- Zero Moderation Markups: Saved 100% of traditional PMR agency moderation markups by utilising Omnitheia’s built-in experts and moderation capabilities.
- Consolidated Intelligence Spend: Avoided purchasing expensive, temporary BI database subscriptions for the new disease area.
Follow Omnitheia on LinkedIn for real-time insights and strategy discussions.
